“A survey of opioid treatment programs finds that the proportion offering on-site testing for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) declined substantially between 2000 and 2011, despite guidelines recommending routine opt-out HIV testing in all health care settings, according to a study appearing in the December 25 issue of the Journal of the American Medical Association (JAMA).
From 2000 to 2011, the absolute number of programs offering testing for HIV, STIs, and the Hepatitis C virus (HCV) increased but the percentage offering on-site testing for HIV declined by 18 percent and for STIs by 13 percent. There was no change for HCV testing. More than 75 percent of public programs offered on-site testing for each infection, with no change over time.
Declines were most pronounced in for-profit programs.”
Source: MedicalExpress.com – December 24, 2013